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Abstract 
Up to 30% of sentinel node-negative patients develop metastases during 
follow-up. Negative sentinel node biopsies (SNB) can be classified to false 
(FN) and true negative (TN) categories. Little attention has been paid to the 
characteristics and outcomes of patients who experience direct distant 
metastasis following TN-SNB. In this retrospective study of a melanoma 
database at Tampere university hospital we analyzed characteristics and 
outcome following metastases after TN-SNB. A total of 506 patients 
underwent SNB between 2006 and 2016. After review, SNBs were classified 
FN, TN and true positive (TP). Follow-up was performed until 30.4.2019.  
Of SN-negative patients, 74 of 396 (19%) developed recurrence, including 
17 (4%) local, 22 (6%) regional lymph node (FN) and 35 (9%) direct distant 
metastases (TN-D). False negative rate was 16% and negative predictive 
value 93.8%. Locoregional recurrences occurred earlier compared to distal 
metastases (median of 2.14 /2.93 years). Compared to patients without 
recurrence, thickness ≥ 2 mm (univariable p<0.001), male gender (p=0.021), 
nodular melanoma (p=0.001), ulceration (p<0.001) and location in upper 
limb region (p=0.062) were predictors of TN-D. The 5-year melanoma 
specific survival in TN-D patients did not differ significantly from TP 
patients (2.36 /2.26 years).  
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TN-D is associated with nodular melanomas in upper 
limb region, male gender, cervical SNBs and ulcerated 
tumors with Breslow thickness ≥ 2 mm. These patients 
should be considered at high-risk relapse and mortality. 
Surveillance imaging to detect distant metastases is 
mandatory regardless of SNB status. In future, inclusion 
criteria for therapy trials for high-risk SNB-negative 
patients might also be worth considering. 
 
Keywords: Melanoma; Sentinel node- negative; False 
negative; Recurrence; Metastasis 
 
1. Introduction 
The standard treatment of melanoma is wide local 
excision of primary tumor and sentinel node biopsy 
(SNB) for staging purposes [1]. The utility of SNB 
correlates with depth of invasion of the primary tumor, 
and is a routine management in patients with melanoma 
thicker than 1 mm and may be considered for thin 
lesions with high-risk characteristics (e.g. ulceration) 
[2]. SN status together with Breslow thickness and 
ulceration have been verified as the most important 
prognostic factors in melanoma [3]. However, the value 
of SNB as a prognostic marker may be reduced by the 
existence of false negative results or distant recurrence 
after negative SNB. The probability of developing 
distant or local recurrence following a negative SNB 
during follow-up ranges from 4% to 29% [4]. Negative 
SNBs can be classified to false negative (FN) and true 
negative (TN) categories. A FN-SNB has been defined 
as a recurrence of melanoma in the previously biopsied 
lymph node basin [4]. False negative results have been 
reported in 2.0-18.4% of patients [5]. Possible etiologies 
of FN-SNB include poor radiographic localization of 
SN, failed pathologic evaluation and failure of surgical 
technique to identify the SN [4]. The presence of 
multiple SN basins and regions of the body where 
lymphatic drainage is known to be complex (head/neck) 
has the potential to contribute to an increased risk of 
recurrence after negative SNB [4]. 
 
True negative SNB (TN-SNB) is defined as negative 
SNB without regional recurrence in the previously 
sampled node basin [6]. It has been suggested that 
melanoma which recurs after negative SNB may exhibit 
different tumor biology. The development of distant 
metastases despite negative SNB may be due to local 
regression of primary melanoma lesions, immunologic 
clearance of the melanoma in the regional lymph node 
basin, direct hematogenous spread of the disease or the 
presence of melanoma leading to obstruction of 
lymphatic drainage [4]. The prior research has primarily 
attempted to identify clinical factors associated with the 
occurrence of FN-SNB and the impact of FN-SNB on 
survival outcome [4, 6, 7, 8]. Patients with FN-SNB 
have had a worse prognosis than patients with positive 
SNB [5]. However, little attention has been paid to the 
characteristics and outcomes of patients who experience 
direct distant metastasis of melanoma following TN-
SNB. The purpose of this study was to identify 
clinicopathologic characteristics and outcome associated 
with patients with metastases after TN-SNB. 
 
2. Materials and Methods 
In this retrospective study, we included 506 patients 
who underwent successful SNB for cutaneous 
melanoma at the Tampere university hospital (Finland) 
between 2006 and 2016. Permission to access the 
clinical records of the melanoma patients for the study 
was obtained from the scientific center of Tampere 
University Hospital. Retrospective review of records 
was performed to determine following information: age, 
gender, primary tumor site (head/neck, trunk, upper 
limb, lower limb), tumor characteristics (Breslow, 
ulceration, subtype (superficial spreading melanoma, 
(SSM), nodular melanoma (NM), lentigo maligna 
melanoma (LMM) and other (including acral 
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melanoma)) and time of diagnosis. Clinical outcomes 
regarding SN included the lymph node basins (cervical, 
axillary, inguinal, other), number of SNs removed and 
results of the SNB. TP-SNB was defined as any positive 
SNB. Negative SNBs were divided to false negative 
(FN), true negative (TN) with distant metastasis (TN-
D), TN without recurrence (TN-NoR) and negative SNB 
with local recurrence (LR). FN was defined as 
recurrence of melanoma in the previously biopsied 
lymph node basin. Time of the recurrence was recorded 
as well as time of death and reason for death 
(melanoma, other).  
 
Our technique for SNB is described here briefly. All 
consecutive patients with a Breslow lesion >1 mm or 
0.75-1 mm with ulceration and/or mitotic activity 
>1/mm
2
 were considered for lymphatic mapping and 
SNB. A preoperative lymphoscintigraphy was 
performed for all patients using 99mTc labeled human 
albumin colloid injected intra-dermally before the 
operation. Patent blue was injected intra-dermally 10 
minutes before incision (until October 2013, after which 
it was not used). Starting in October 2013, single-
photon emission computerized tomography/computed 
tomography (SPECT/CT) was performed for all 
melanoma patients preoperatively. Intraoperative 
identification of the SN was done with a handheld 
gamma probe. Radioactive nodes that had count >10% 
of the most radioactive node were also considered as 
SNs. Histopathologic analysis of SN consisted of 
sectioning and staining with hematoxylin and eosin. 
Starting in March 2012, the immunohistochemical 
markers S-100, Melan-A and HMB-4 were used 
routinely. 
 
2.1 Statistical analysis 
False negative rate (FNR) was calculated as the ratio 
between the false negatives and the total of false 
negative and true positives. Negative predictive value 
(NPV) was calculated as [Number of true 
negatives/(number of false negatives +number of true 
negatives)]. Predictive factors for SN were calculated by 
univariable using Mann-Whitney test, Pearson chi-
square test or Fisher’s exact test, and by multivariable 
performing logistic regression analysis. Disease-free 
survival (DFS) was defined as the time between the 
time of diagnosis and detected recurrence. Survival was 
calculated from the time of diagnosis to death, either 
from melanoma (melanoma-specific survival, MSS) or 
other causes (overall survival, OS). Time-to-event 
analyses were performed using Cox proportional hazard 
regression analysis. A p-value of <0.005 was considered 
significant. All analyses were performed using IBM 
SPSS Statistics for Windows, version 25.0 software 
(IBM Corp., Armonk, NY). 
 
3. Results 
3.1 Overall demographics 
From 2006 to 2016, 506 patients (274 (54%) men and 
232 (46%) women) underwent SNB. Follow-up was 
performed until 30.4.2019. The median age of patients 
was 68 (range 21-90) years in men and 70 (range 36-90) 
years in women. The median Breslow thickness was 2.0 
(IQR 1.2-4.0) mm in men and 1.8 (IQR 1.1-3.0) mm in 
women. The most common (66%, 334/506) histologic 
subtype was superficial spreading melanoma (SSM), 
followed by nodular melanoma (NM) (20%, 102/506), 
lentigo maligna melanoma (LMM) (8%, 42/506) and 
other (including acral melanoma) (6%, 28/506). The 
most common location of melanoma was trunk 
(182/506, 36%), followed by lower limb (116/506, 
23%), upper limb (110/506, 22%) and head/neck area 
(98/506, 19%). Of 506 melanomas, 200 (40%) were 
ulcerated. One hundred and ten of 506 patients (22%) 
had nodal metastasis in SNB and were considered TPs. 
A total of 396 patients out of 506 (78%) did not have 
metastasis in SNB and were considered SN-negatives. 
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False negative rate was 16% and negative predictive 
value 93.8%. 
 
3.2 Recurrence patterns  
The majority (322/396, 81%) of SN-negative patients 
did not have recurrence during the study period. A total 
of 74 out of 396 (19%) SN-negative patients developed 
recurrence, including 17 (4.3%) local (LR), 22 (5.5%) 
regional lymph node (FN) and 35 (8.8%) direct distant 
metastases (TN-D) (Table 1). Of SN-positive patients, 
55 of 110 (50%) patients developed metastases, 
including 39 (71%) distant and 16 (29%) locoregional 
metastases. In SNB-negative patients locoregional 
recurrences occurred earlier with DFS median of 2.14 
years (IQR 1.09-3.50, range 0.3-4.8) compared to 2.93 
(IQR 1.15-4.49, range 0.3-7.4) for distal metastases. 
The median DFS in TPs was 1.44 (IQR 0.82-3.08, range 
0.1-4.9). 
 
3.3 TN-D compared with TN-NoR and TP groups 
We compared the characteristics of the TN-D patients to 
those of the TN-NoR and TP groups (Table 1). 
Compared with TN-NoR, TN-D patients were older 
(univariable p=0.004, multivariable OR 1.02 (0.99-
1.05)), more male predominant p=0.021, OR 1.87 (0.79-
4.49)) with Breslow thickness thicker than 2mm 
(p<0.001, OR 4.11 (1.55-10.9) and ulcerated (p<0.001, 
OR 1.73 (0.77-3.93). Nodular melanomas were more 
common in TN-D group (p=0.001, OR 1.97 (0.78-4.95). 
Upper limb region (OR 1.67 (0.55-5.09) melanomas 
were more common in TN-D group compared to TN-
NoR group. In contrast, relative to TP, TN-D patients 
were also more male predominant (p=0.302, OR 1.77 
(0.63-4.97) but did not have significantly increased 
Breslow thickness (p=0.580, OR 1.06 (0.33-3.41)) and 
were less commonly ulcerated (p=0.231, OR 0.37 (0.14-
0.99)). Sentinel lymph node basin was more commonly 
in head/neck region in TN-Ds compared to both TN-
NoR and TP (28% compared to 7% and 11% 
respectively). Number of sentinel nodes removed did 
not differ significantly between TN-D, TN-NoR and TP 
groups (with median of 2.6 (range 1-6), 2.0 (1-12), 2.75 
(range 0-8) respectively). 
 
3.4 Survival analysis 
The 5-year MSS for the entire cohort (n=506) was 5.23 
(IQR 3.40-8.42, range 0.4-13.3) years and 78.7%. The 
5-year MSS was similar between the TN-D and the TP 
group (2.36 years (IQR 1.49-3.29, range 0-5.0) 
compared to 2.26 years (IQR 1.49-3.29, range 0-5.0), 
age-adjusted HR 1.54 (95% CI 0.84-2.81). The TN-NoR 
group had significantly better MSS compared with both 
the TP and the TN-D groups with 5-year MSS of 5.00 
(IQR 3.28-5.00, range 0.4-5.0). 
 
4. Discussion 
Our study demonstrates that direct distant metastases 
after negative SNB are associated with an ulcerated 
tumor with Breslow thickness ≥ 2 mm, more commonly 
upper limb primary tumor site, cervical SNB location, 
higher number of nodular melanomas and male gender. 
Consistent with previous publications [4, 5, 9, 10] on 
SNB-negative patients (including FN patients), our 
study revealed increasing Breslow thickness and 
ulceration to be predictors for distant recurrence. Of 
SN-negative patients with direct distant metastases, 
80% of patients had Breslow thickness ≥ 2 mm, which 
has been significantly associated with relapse in 
melanomas in general [2]. Over half of TN-D 
melanomas were ulcerated compared to melanomas 
without recurrence, of which 26% were ulcerated. 
According to studies, the presence of ulceration seems 
to be strongly associated with hematogenous 
dissemination of metastasis (2), which may also explain 
direct distant metastases in our cases. 
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Age (yrs) (Median (Md) ±  
range) 
Local 
(LR) 
(N=17)  
Regional 
(FN) 
(N=22)  
Distant 
(TN-D) 
(N=35)  
No 
recurrence 
(TN-NoR) 
(N=322)  
Positive 
SNB (TP)
(N=110)  
TN-D vs. TN-NoR  
(n=357) 
TN-D vs. TP  
(n=145) 
Univariable  Multivariable  Univariable  Multivariable 
p-value OR (95% CI) p-value OR (95% CI) 
69 (49-93) 59 (41-91) 71 (48-86) 66 (18-97) 68 (21-90) 0.004 1.02 (0.99-1.05) 0.034 1.04 (0.997-1.09) 
Sex, n (%)  0.021 - -  0.302 -  - 
    Men 4 (24) 13 (59) 25 (71) 164 (51) 68 (62) - 1.87 (0.79-4.49) - 1.77 (0.63-4.97) 
    Women 13 (76) 9 (41) 10 (29) 158 (49) 42 (38) - 1.00 - - 1.00 - 
Ulceration, n (%)  <0.001 - -  0.231 -  -  
    No 9 (53) 10 (45) 15 (43) 237 (74) 35 (32) - 1.00 -  -  1.00 - 
    Yes 8 (47) 12 (55) 20 (57) 85 (26) 75 (68) - 1.73 (0.77-3.93) - 0.37 (0.14-0.99) 
Tumor thickness (mm), Md 
(IQR) 
3.5 (2.5-4.0) 2.7 (1.9-5.1) 3.5 (2.0-6.5) 1.5 (1.1-2.4) 3.0 (2.0-5.0) <0.001 -  - 0.580 -  - 
    Br <2 mm, n (%) 1 (6) 6 (27) 7 (20) 206 (64) 27.(24) - 1.00 -  - 1.00 -  
    Br ≥2 mm, n (%) 16 (94) 16 (73) 28 (80) 116 (36) 83 (76) 4.11 (1.55-10.9) 1.06 (0.33-3.41) 
Subtype, n (%)  0.001 - - 0.274 -  - 
   SSM 9 (53) 14 (64) 16 (46) 239 (74) 56 (51) - 1.00 - - 1.00 -  
   LMM 2 (12) 3 (14) 5 (14) 26 (8) 6 (5) - 3.28 (0.89-12.1) - 6.32 (1.14-35.0) 
   NM 4 (23) 3 (14) 13 (37) 44 (14) 38 (35) - 1.97 (0.78-4.95) - 1.67 (0.59-4.75) 
Tumor location, n (%)  0.062 - -  0.002 -  -  
  Head and neck 2 (12) 3 (14) 10 (29) 69 (21) 14 (13) - 1.00 - - 1.00 - 
  Trunk 7 (41) 5 (23) 11 (31) 114 (36) 45 (41) - 1.10 (0.35-3.48) - 0.38 (0.12-1.20) 
  Upper limb 2 (12) 5 (23) 10 (29) 73 (23) 20 (18) - 1.67 (0.55-5.09) - 1.13 (0.31.4.09) 
  Lower limb 6 (35) 8 (36) 5 (14) 66 (20) 31 (28) - 0.43 (0.07-2.47) - 0.12 (0.02-0.67) 
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Univariable analyses were performed using Mann-Whitney test, Pearson chi-square or Fisher’s exact test. In multivariable logistic regression analysis, adjusting factors (age, sex, 
categorized tumor thickness and tumor location) were included simultaneously into the model. Results were shown by odds ratios (OR) with 95% confidence intervals (CI). 
SSM=superficial spreading melanoma, LMM=lentigo maligna melanoma, NM=nodular melanoma. Local (LR)=local recurrence, Regional (FN)=regional lymph node basin 
recurrence (false negative cases), Distant (TN-D)=direct distant metastasis after true negative sentinel node biopsy, No Recurrence (TN-NoR)=melanoma cases with no 
recurrence during follow-up, Positive SNB (TP)=melanoma cases with positive sentinel node biopsy (true positive cases). 
Table 1: Clinicopathologic characteristics and outcome for patients after sentinel node biopsies (SNB).
Exitus during follow-up, n (%)  <0.001 - -  0.008 -  -  
  of melanoma 3 (18) 11 (50) 21 (60) 0 (0) 33 (30) - - -  - -  - 
  of other reasons  2 (12)  1 (5)  2 (6)  50 (16)  15 (14)  - - - - - - 
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In our study, the location of melanoma in head/neck 
region was not statistically associated with distant 
recurrences after true negative SNB in multivariate 
analysis, which has been found in previous studies with 
false negative cases [4, 5, 6, 10]. It has been suggested 
that the increased rate of recurrences despite of negative 
SNB (false negative) in the head and neck region may 
be rated to technical factors, including the complex 
drainage patterns of that region [6]. Unexpected or 
aberrant lymph drainage patterns are expected in head 
and neck melanomas more than melanomas located on 
upper and lower extremity [10]. This supports more 
routine use of SPECT-CT in this population [7]. We 
studied occurrence of direct metastases after true 
negative SNB and this could explain this difference 
compared to other studies. We have used SPECT-CT 
from October 2013 to all melanoma patients routinely 
preoperatively. Before that, conventional 2-dimensional 
lymphoscintigraphy was performed. The impact of this 
change in SNB results was not evaluated in this study. 
 
In our study, however, the higher number of melanoma 
in the upper limb region was associated with direct 
distant metastases. The upper extremity primary has 
been reported earlier [11] to predict SN+ status but has 
not been connected to SN-negative melanomas. In our 
study, 18% of TP patients compared to 28% of TN-Ds 
had melanoma in upper limb area. The most common 
location of SN in upper limb region is axilla but the 
lymphatic drainage from upper parts of upper limb 
might also go to cervical area. In our study, sentinel 
lymph node basin was more commonly in head/neck 
region in TN-Ds compared to both TN-NoRs and TPs. 
 
On the other hand, the question of reason for recurrence 
might not be the location of SNs. Several other 
explanations have been suggested. The possibility of 
immunologic clearance of the melanoma in the regional 
lymph node basin prior to SNB may be responsible for 
the development of distant metastases despite negative 
SNB [9]. It has been also suggested that especially 
ulceration may reflect a distinct subtype of melanoma 
with a higher vascular density and greater local host 
response [12]. Similarly, changes in the tumor 
microenvironment in ulcerated melanoma may interact 
differently with the immune system [5]. Metastatic 
melanoma leading to obstruction of lymphatic drainage 
and direct hematogenous spread of the disease have 
been proposed as a possible etiology of metastatic 
disease following a negative SNB [4].  
 
An association between NM and melanoma recurrence 
has been described in SN-negative patients [10]. In our 
study 37% of TN-D patients had NM compared to 14% 
of patients with no recurrence. It has been hypothesized 
that the aggression of NM may be because of decreased 
recognition by immune system, as represented by a 
lower levels of tumor-infiltrating lymphocytes 
compared to SSMs [13]. It is possible that differences in 
the immunogenicity of the primary melanoma are 
relevant for recurrence after negative SNB [5] This 
difference in the levels of tumor-infiltrating 
lymphocytes, however, appeared to be prominent in 
melanomas thinner than 2mm, while the difference was 
no longer significant in melanomas thicker than 2 mm 
[13]. 
The relationship of gender to TN-D is curious and 
currently unexplained. While it is well known that male 
gender is an adverse prognostic factor in melanoma, it is 
not clear why this would be related to the accuracy of 
lymphatic mapping [6] On the other hand, immunologic 
differences in response to tumor may contribute toward 
sex differences in melanoma outcome. Men may show 
less antitumor surveillance, resulting in reduced 
immune recognition of nodular melanoma. For example, 
lower levels of tumor-infiltrating lymphocytes in NMs 
compared to SSMs have been observed only in men 
[13].  
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The other major issue examined in this study is the 
impact of TN-D on outcome. The prior research has 
primarily attempted to identify clinical factors 
associated with the occurrence of FN-SNB and the 
impact of FN-SNB on survival outcome [4, 6, 7, 8]. 
According to other studies, patients with FN-SNB have 
worse prognosis than patients with positive SNB at least 
in longer than 5 years follow-up [5, 6]. Little attention 
has, however, been paid to the characteristics and 
outcomes of patients who experience direct distant 
metastasis of melanoma following TN-SNB. In our 
study, when analyzed with 5 years follow-up, there was 
no significant difference between TPs and TN-Ds. It 
should be, however, noted that most recurrences in 
melanoma occurs within 5 years and 80% of patients 
who experience recurrences after the first 5 years 
follow-up are SNB-negative. Thus, the late recurrences 
in patients with negative SNB may influence the 10-
year predictive role of SNB status in the Cox regression 
analysis [2]. It is important, in future, to analyze 10 
years MSS also in our study cohort.  
 
This study has the limitations inherent to any 
retrospective study with potential confounding variables 
that we have not accounted for. The current study is not 
able to provide a causative explanation for the direct 
distant metastases after negative SNB, although the 
identification of various patient and tumor factors 
associated with metastases would argue for at least a 
partial role for tumor biology. A prospective study with 
a larger sample of SNB-negative patients with 
subsequent recurrence would be helpful to refine the 
analysis of risk factors in TN-D patients. 
 
It would be impractical and not cost efficient to propose 
that all patients with negative SNB should undergo 
increased surveillance. We undertook this study to 
examine the factors and clinical implications of their 
occurrence that are associated with TN-D. The current 
study identifies high- risk groups for TN-D events for 
whom counseling and change in clinical management 
and surveillance would be appropriate. While the value 
of earlier detection of metastatic disease has been at best 
unclear historically, with the recent advent of effective 
novel therapeutic agents for melanoma, changes might 
be possible. In future, inclusion criteria for therapy trials 
for high-risk SNB-negative patients might also be worth 
considering. 
  
5. Conclusion 
In this study, the association of TN-D with nodular 
melanomas more commonly in upper limb tumor site, 
cervical SNB location, male gender and ulcerated 
tumors with Breslow thickness ≥2 mm was described. 
These patients should be considered at high-risk relapse 
and mortality and we therefore recommend stricter 
follow-up to these patients regardless of SNB status. In 
future, inclusion criteria for therapy trials for high-risk 
SNB-negative patients might also be worth considering.  
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